[go: up one dir, main page]

PL2376086T3 - Leczenie atrofii pochwy u kobiet z ryzykiem patologii sercowo-naczyniowej - Google Patents

Leczenie atrofii pochwy u kobiet z ryzykiem patologii sercowo-naczyniowej

Info

Publication number
PL2376086T3
PL2376086T3 PL09781638T PL09781638T PL2376086T3 PL 2376086 T3 PL2376086 T3 PL 2376086T3 PL 09781638 T PL09781638 T PL 09781638T PL 09781638 T PL09781638 T PL 09781638T PL 2376086 T3 PL2376086 T3 PL 2376086T3
Authority
PL
Poland
Prior art keywords
women
treatment
vaginal atrophy
cardiovascular pathology
pathology risk
Prior art date
Application number
PL09781638T
Other languages
English (en)
Inventor
Álvaro ACEBRÓN FERNÁNDEZ
Dolores Blanco Lousame
Jaime Moscoso Del Prado
Concepción NIETO MAGRO
Original Assignee
Itf Res Pharma S L U
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41050933&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2376086(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Itf Res Pharma S L U filed Critical Itf Res Pharma S L U
Publication of PL2376086T3 publication Critical patent/PL2376086T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
PL09781638T 2008-12-19 2009-08-07 Leczenie atrofii pochwy u kobiet z ryzykiem patologii sercowo-naczyniowej PL2376086T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200803623A ES2344675B1 (es) 2008-12-19 2008-12-19 Uso de estriol en la preparacion de una formulacion farrmaceutica para el tratamiento de atrofia vaginal en mujeres con riesgo de patologiacardiovascular.
EP09781638.3A EP2376086B1 (en) 2008-12-19 2009-08-07 Treatment of vaginal atrophy in women with cardiovascular pathology risk
PCT/EP2009/060304 WO2010069621A1 (en) 2008-12-19 2009-08-07 Treatment of vaginal atrophy in women with cardiovascular pathology risk

Publications (1)

Publication Number Publication Date
PL2376086T3 true PL2376086T3 (pl) 2019-05-31

Family

ID=41050933

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09781638T PL2376086T3 (pl) 2008-12-19 2009-08-07 Leczenie atrofii pochwy u kobiet z ryzykiem patologii sercowo-naczyniowej

Country Status (24)

Country Link
US (1) US8835414B2 (pl)
EP (1) EP2376086B1 (pl)
JP (1) JP2012512818A (pl)
KR (1) KR101734380B1 (pl)
CN (1) CN102325533A (pl)
CA (1) CA2747314C (pl)
CL (1) CL2011001493A1 (pl)
CO (1) CO6382128A2 (pl)
CY (1) CY1120971T1 (pl)
DK (1) DK2376086T3 (pl)
EC (1) ECSP11011211A (pl)
ES (2) ES2344675B1 (pl)
HR (1) HRP20182022T1 (pl)
HU (1) HUE040394T2 (pl)
LT (1) LT2376086T (pl)
MA (1) MA32984B1 (pl)
MX (1) MX2011006696A (pl)
PE (1) PE20120496A1 (pl)
PL (1) PL2376086T3 (pl)
PT (1) PT2376086T (pl)
RU (1) RU2555752C2 (pl)
SI (1) SI2376086T1 (pl)
SM (1) SMT201800648T1 (pl)
WO (1) WO2010069621A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3242687B1 (en) * 2015-01-05 2020-12-30 B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University Nanoparticles and methods for preparation thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1866M (fr) 1961-04-07 1963-06-17 Vismara Francesco Spa Nouveaux éthers des hormones oestrogenes.
ATE151286T1 (de) 1983-11-14 1997-04-15 Columbia Lab Inc Bioadhäsive mittel
US5719197A (en) 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
DK0431719T3 (da) 1989-10-31 1995-02-27 Columbia Lab Inc Vaginalt vævsbefugtende præparat
WO1991006289A1 (en) 1989-10-31 1991-05-16 Watson Laboratories, Inc. Mucoadhesive carrier for delivery of therapeutical agent
US5340586A (en) * 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
US5543150A (en) 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
US5667492A (en) 1994-10-07 1997-09-16 Columbia Laboratories, Inc. Use and composition of an anti-sexually transmitted diseases formulation
AT408067B (de) 1995-03-17 2001-08-27 Gebro Pharma Gmbh Pharmazeutische zusammensetzung zur topischen applizierung und verfahren zu ihrer herstellung
US5741525A (en) 1995-10-24 1998-04-21 Marshall University Research Corporation Vaginal pharmaceutical hydrogen peroxide composition
IT1275816B1 (it) 1995-10-27 1997-10-17 Montefarmaco Spa Composizioni farmaceutiche solide per uso vaginale
AU714797B2 (en) 1996-06-14 2000-01-13 Mcneil-Ppc, Inc. Moisture containing compositions that are spreadable onto and adherable to biomembranes, methods of making and use thereof
IT1284874B1 (it) 1996-08-02 1998-05-22 Farmigea Spa Complessi bioadesivi di polycarbophil e farmaci antifungini o antiprotozoari azolici
US5942243A (en) 1996-11-12 1999-08-24 Polytherapeutics, Inc. Mucoadhesive compositions for administration of biologically active agents to animal tissue
ATE442844T1 (de) 1996-11-14 2009-10-15 Lipomedica Ehf Topische zusammensetzungen enthaltend als therapeutisch aktiven wirkstoff ein monoglycerid zur behandlung von schleimhautinfektionen
DE69819748T2 (de) 1997-09-12 2004-09-30 Columbia Laboratories (Bermuda) Ltd. Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
US6159491A (en) 1999-02-12 2000-12-12 Biovector Technologies, Inc. Prolonged release bioadhesive vaginal gel dosage form
DE69942774D1 (de) 1999-02-26 2010-10-28 Novartis Vaccines & Diagnostic Verwendung von bioadhaesiven und adjuvantien für die mukosale anwendung von antigenen
UA74168C2 (uk) 1999-10-05 2005-11-15 Коламбіа Леборетеріс (Бермуда) Лімітед Лікування ендометріозу або безпліддя, або покращення плідності та застосування бета-адренергічного агоніста для виробництва лікарського засобу
AU778498B2 (en) 1999-10-22 2004-12-09 Lif-Hlaup Ehf. Bio-Gels Pharmaceuticals Inc. Pharmaceutical composition for treatment of mucosal epithelial ulceration and/or erosion
ATE442147T1 (de) * 2000-01-18 2009-09-15 Bayer Schering Pharma Ag Pharmazeutische zubereitung enthaltend drospirenon
ATE485837T1 (de) 2000-08-03 2010-11-15 Antares Pharma Ipl Ag Zusammensetzung zur transdermalen und/oder transmukosalen verabreichung von wirkstoffen, die ausreichende therapeutische spiegel garantiert
US20040092494A9 (en) 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
JP3655846B2 (ja) 2001-06-27 2005-06-02 埼玉日本電気株式会社 Ｃｄｍａ移動通信システム、及びその呼切断防止方法
ES2237298B1 (es) * 2003-07-16 2006-11-01 Italfarmaco, S.A. Formulaciones mucoadhesivas semisolidas.
EP1912623A2 (en) 2005-08-12 2008-04-23 Drugtech Corporation Estrogen compositions and therapeutic methods of use thereof
WO2007070067A1 (en) 2005-12-16 2007-06-21 Lyle Corporate Development, Inc. Regeneration of vaginal tissue with non-systemic vaginal administration of estrogen
US20070264309A1 (en) * 2006-01-20 2007-11-15 Chollet Janet A Method Of Treating Atrophic Vaginitis
EP1872775A1 (en) * 2006-06-29 2008-01-02 Polichem S.A. Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders
WO2008089405A1 (en) 2007-01-19 2008-07-24 Neurosci, Inc. Composition of multiple hormones delivered vaginally in a single cream
ES2310968B1 (es) * 2007-06-25 2010-02-08 Italfarmaco, S.A. Uso de estriol en bajas dosis.

Also Published As

Publication number Publication date
EP2376086A1 (en) 2011-10-19
RU2555752C2 (ru) 2015-07-10
HRP20182022T1 (hr) 2019-01-25
ES2707873T3 (es) 2019-04-05
WO2010069621A8 (en) 2011-07-21
SI2376086T1 (sl) 2019-02-28
CL2011001493A1 (es) 2012-01-13
ES2344675B1 (es) 2011-04-28
US20110312929A1 (en) 2011-12-22
CA2747314A1 (en) 2010-06-24
MX2011006696A (es) 2011-07-28
LT2376086T (lt) 2019-01-10
CA2747314C (en) 2017-04-18
KR20110108358A (ko) 2011-10-05
MA32984B1 (fr) 2012-01-02
EP2376086B1 (en) 2018-09-19
PE20120496A1 (es) 2012-05-04
CN102325533A (zh) 2012-01-18
ECSP11011211A (es) 2011-08-31
KR101734380B1 (ko) 2017-05-11
DK2376086T3 (en) 2018-12-10
HUE040394T2 (hu) 2019-03-28
ES2344675A1 (es) 2010-09-02
SMT201800648T1 (it) 2019-01-11
RU2011127702A (ru) 2013-01-27
JP2012512818A (ja) 2012-06-07
US8835414B2 (en) 2014-09-16
CY1120971T1 (el) 2019-12-11
PT2376086T (pt) 2018-12-18
CO6382128A2 (es) 2012-02-15
WO2010069621A1 (en) 2010-06-24

Similar Documents

Publication Publication Date Title
IL216128A (en) Antibodies to ngf with increased in vivo stability
IL220055A0 (en) Adherent cells from placenta and use of same in disease treatment
GB2474083B (en) Improvements in and relating to ophthalmic instruments
ZA201100974B (en) Treatment of autoimmune and inflammatory disease
PL2614832T3 (pl) Diagnostyka i leczenie stanu przedrzucawkowego
IL217748A0 (en) Methods and compositions for diagnostics use in cancer patients
EP2410990A4 (en) COMPOSITIONS AND METHODS FOR CONTRAST GAINING IN IMAGING
SI2491005T1 (sl) Uporaba 4-(etil(dimetil)amonio)butanoata pri zdravljenju bolezni srca in oĺ˝ilja
GB2474079B (en) Improvements in and relating to ophthaimic instruments
GB0917612D0 (en) In vivo imaging agents
PL2328589T3 (pl) Leczenie atrofii pochwy u kobiet z ryzykiem patologii nowotworowej
GB0903260D0 (en) Diagnostic method and kit
SMT201800648T1 (it) Trattamento di atrofia vaginale in donne con rischio di patologia cardiovascolare
ZA201201369B (en) Improvements in and relating to cable-barriers
GB2458569B (en) Improvements in and relating to cloches
EP2478113A4 (en) COMPOSITIONS AND METHODS FOR EVALUATING BIOLUMINESCENCE IN VIVO
GB0821594D0 (en) Improvements in or relating to the treatment of tissue damage
GB0820879D0 (en) Improvements in and relating to walls
IL220241A0 (en) Use of transferrin in treatment of beta-thalassemias
GB2474082B (en) Improvements in and relating to ophthalmic instruments
IL219444A (en) Procine for use in the treatment of blood cell infections
ZA201206853B (en) Composition for use in water treatment
GB0822250D0 (en) Improvements in and relating to karabiners
HU0800726D0 (en) Process and kit
GB0917739D0 (en) Improvements in and relating to wheelchairs